Ignite Creation Date:
2025-12-25 @ 3:45 AM
Ignite Modification Date:
2025-12-26 @ 2:32 AM
Study NCT ID:
NCT00754702
Status:
TERMINATED
Last Update Posted:
2015-09-28
First Post:
2008-09-17
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077235', 'term': 'Vinorelbine'}, {'id': 'D000077341', 'term': 'Lapatinib'}], 'ancestors': [{'id': 'D014748', 'term': 'Vinca Alkaloids'}, {'id': 'D046948', 'term': 'Secologanin Tryptamine Alkaloids'}, {'id': 'D026121', 'term': 'Indole Alkaloids'}, {'id': 'D000470', 'term': 'Alkaloids'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D007211', 'term': 'Indoles'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D054836', 'term': 'Indolizidines'}, {'id': 'D007212', 'term': 'Indolizines'}, {'id': 'D011799', 'term': 'Quinazolines'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 16}}, 'statusModule': {'whyStopped': 'Poor accrual', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2008-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2015-09', 'completionDateStruct': {'date': '2011-03', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2015-09-25', 'studyFirstSubmitDate': '2008-09-17', 'studyFirstSubmitQcDate': '2008-09-17', 'lastUpdatePostDateStruct': {'date': '2015-09-28', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2008-09-18', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2011-03', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Overall response rate', 'timeFrame': '3 - 6 month'}], 'secondaryOutcomes': [{'measure': 'Progression Free Survival', 'timeFrame': '1 year'}, {'measure': 'Toxicity profile', 'timeFrame': '21 days'}, {'measure': 'Overall Survival', 'timeFrame': '1 year'}, {'measure': 'Quality of life assessment', 'timeFrame': '42 days'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Vinorelbine metronomic-lapatinib', 'Chemotherapy', 'Targeted therapy'], 'conditions': ['Breast Cancer']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate the safety and efficacy of metronomic oral vinorelbine taken three times a week plus daily lapatinib without break, as salvage treatment in patients with metastatic breast cancer.', 'detailedDescription': 'Continuous administration of oral vinorelbine, given three times a week (metronomic) is feasible and exceptionally well tolerated at doses up to 50 mg. Early results show activity against refractory tumors and provide evidence towards clinical proof of efficacy for metronomic chemotherapy. Recently, lapatinib plus capecitabine was proven superior to capecitabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Histologically- or cytologically- confirmed metastatic breast adenocarcinoma\n* Age 18-75 years\n* HER2 status positive according to the local institution reported grade 3+ staining intensity (on a scale of 0 to 3) by means of immunohistochemical analysis or grade 2+ staining intensity by means of immunohistochemical analysis with gene amplification on fluorescence in situ hybridization\n* Previous therapies had to include, regimens containing an anthracycline and a taxane\n* Previous treatment with trastuzumab, alone or in combination with chemotherapy for locally advanced or metastatic disease, is required\n* Measurable disease as defined by the presence of at least one measurable lesion (except bone metastases, ascites or pleural effusions)\n* Performance status (WHO) 0-2\n* Adequate liver (serum bilirubin \\<1.5 times the upper normal limit; AST and ALT \\<2.5 times the upper normal limit in the absence of demonstrable liver metastases, or \\<5 times the upper normal limit in the presence of liver metastases); adequate renal function (serum creatinine \\<1.5 times the upper normal limit); and bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L) function\n* No radiation of measurable disease (except brain metastases)\n* No progressive brain metastases according to clinical or radiological criteria\n* No brain metastases without prior radiation therapy\n* Written informed consent\n\nExclusion Criteria:\n\n* Patient unable to take oral medication\n* Active infection\n* History of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias)\n* Other invasive malignancy except nonmelanoma skin cancer\n* Psychiatric illness or social situation that would preclude study compliance\n* Pregnant or lactating women'}, 'identificationModule': {'nctId': 'NCT00754702', 'briefTitle': 'Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer', 'organization': {'class': 'OTHER', 'fullName': 'University Hospital of Crete'}, 'officialTitle': 'Vinorelbine Metronomic Plus Lapatinib as Salvage Therapy for Patients With Overexpressing HER-2 Metastatic Breast Cancer. A Multicenter Phase II Study', 'orgStudyIdInfo': {'id': 'CT/08.27'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': '1', 'description': 'Vinorelbine metronomic/Lapatinib', 'interventionNames': ['Drug: Vinorelbine', 'Drug: Lapatinib']}], 'interventions': [{'name': 'Vinorelbine', 'type': 'DRUG', 'otherNames': ['Navelbine'], 'description': 'Vinorelbine p.o (50 mg 3 times a week) until disease progression or appearance of unacceptable toxicity', 'armGroupLabels': ['1']}, {'name': 'Lapatinib', 'type': 'DRUG', 'otherNames': ['Tyverb', 'Tykerb'], 'description': 'Lapatinib p.o every day without interruption disease progression or appearance of unacceptable toxicity', 'armGroupLabels': ['1']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Heraklion', 'state': 'Crete', 'country': 'Greece', 'facility': 'University Hospital of Crete, Dep of Medical Oncology', 'geoPoint': {'lat': 35.32787, 'lon': 25.14341}}, {'city': 'Athens', 'country': 'Greece', 'facility': '"IASO" General Hospital of Athens, 1st Dep of Medical Oncology', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}], 'overallOfficials': [{'name': 'Dimitris Mavrudis, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University Hospital of Crete, Dep of Medical Oncology'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University Hospital of Crete', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'MD', 'investigatorFullName': 'Vassilis Georgoulias, MD', 'investigatorAffiliation': 'University Hospital of Crete'}}}}